Antipsychotics, 2nd Gen
PDL Reference Documents
- Antipsychotic Use in Children - Jun 03, 2021
- SGAs in Children and Adolescents DERP Summary - Apr 01, 2021
- Antipsychotics Class Update - Aug 06, 2020
- Antipsychotics Literature Scan - Mar 21, 2019
- Antipsychotics Literature Scan - Sep 27, 2018
- Oral Antipsychotics - Mar 22, 2018
- Antipsychotics - May 26, 2016
- Second Generation Antipsychotics Class Update - Jan 30, 2014
- Class Update: Second Generation Antidepressant Medications - Apr 26, 2012
- Class Update: Second Generation Antipsychotics - Mar 29, 2012
Drug Use Review Documents
- Antipsychotics in Children - Feb 01, 2024
- Antipsychotic Use in Children (2022 update) - Feb 01, 2024
- Quetiapine Prior Authorization Update - Jun 01, 2023
- Quetiapine - Jun 01, 2023
- Lumateperone (CAPLYTA) - Oct 06, 2022
- Combination Use of Antipsychotics and Other Psychotropic Drugs - Apr 01, 2021
- Expert Consultation for Long term Antipsychotics in Children - Dec 03, 2020
- Bipolar Disorder drug Utilization Evaluation - Oct 01, 2020
- Concurrent Use of Opioids and CNS depressants - Jul 25, 2019
- Adherence Monitoring in Schizophrenia - May 23, 2019
- Schizophrenia Drug Use Evaluation - Mar 21, 2019
- Use of Antipsychotics in Children - Nov 30, 2017
- Quetiapine - Nov 30, 2017
- Antipsychotic Monitoring Policy Evaluation - May 25, 2017
- Compounded Drugs - Mar 31, 2016
- Low Dose Quetiapine - Sep 24, 2015
- Antipsychotic Adherence Monitoring RetroDUR Proposal - Mar 27, 2014
- Retrospective Drug Use Review: Metabolic Monitoring of Antipsychotic in Children - Sep 26, 2013
Newsletters
- February 2023 - Psychotropic Use in Youth Enrolled in the Oregon Health Plan and Youth in Foster Care with an Emphasis on Antipsychotic Prescriptions
- January 2022 - Second-Generation Antipsychotic Use in Children and Adolescents
- March 2021 - Bipolar Disorder: Resources for Primary Care Providers
- July 2019 - Oregon Health Authority Mental Health Clinical Advisory Group (MHCAG) Recommendations for the Treatment of Schizophrenia
- March 2018 - Second Generation Antipsychotic Use in Major Depressive Disorder
- April 2014 - Second Generation Antipsychotics: Are these drugs effective in treating PTSD?
- January 2014 - Strategies for Effective Monitoring and Management of Psychotropics in Children
- August 2013 - Managing Metabolic Side Effects in Children Receiving Antipsychotics
- March 2012 - Current Findings in the Off-Label Use of Atypical Antipsychotics
- November 2011 - Atypical Antipsychotic Drug Class Review
PDL Status Values
Y = preferred
N = non-preferred. Non-preferred drugs listed as N but without clinical drug use criteria are subject to the
Non-Preferred Drugs in Select PDL Classes prior authorization criteria.
New drugs will be listed as N until reviewed by the P&T Committee and are subject to the
New Drug Policy.
V = voluntary non-preferred. Non-preferred mental health drugs are listed as V and prior authorization is not required.
Null (i.e. blank) = indicates the class or specific drug has not been reviewed for PDL placement.
To request a Prior Authorization, please use this form.
Generic Name | Brand Name | Form | PDL Status |
Current Drug Use Criteria | New Drug Evaluation |
---|---|---|---|---|---|
aripiprazole | ARIPIPRAZOLE | TABLET | Y | Age Restriction | |
aripiprazole | ABILIFY | TABLET | Y | Age Restriction | |
asenapine maleate | SAPHRIS | TAB SUBL | Y | Age Restriction | |
asenapine maleate | ASENAPINE MALEATE | TAB SUBL | Y | Age Restriction | |
cariprazine HCl | VRAYLAR | CAPSULE | Y | Age Restriction | |
clozapine | CLOZARIL | TABLET | Y | Age Restriction | |
clozapine | CLOZAPINE | TABLET | Y | Age Restriction | |
lurasidone HCl | LURASIDONE HCL | TABLET | Y | Age Restriction | |
lurasidone HCl | LATUDA | TABLET | Y | Age Restriction | |
olanzapine | ZYPREXA | TABLET | Y | Age Restriction | |
olanzapine | OLANZAPINE | TABLET | Y | Age Restriction | |
quetiapine fumarate | QUETIAPINE FUMARATE ER | TAB ER 24H | Y | Age and Quantity Limits | |
quetiapine fumarate | SEROQUEL XR | TAB ER 24H | Y | Age and Quantity Limits | |
quetiapine fumarate | SEROQUEL XR | TAB24HDSPK | Y | Age and Quantity Limits | |
quetiapine fumarate | SEROQUEL | TABLET | Y | Age and Quantity Limits | |
quetiapine fumarate | QUETIAPINE FUMARATE | TABLET | Y | Age and Quantity Limits | |
risperidone | RISPERDAL | SOLUTION | Y | Age Restriction | |
risperidone | RISPERIDONE | SOLUTION | Y | Age Restriction | |
risperidone | RISPERDAL | TABLET | Y | Age Restriction | |
risperidone | RISPERIDONE | TABLET | Y | Age Restriction | |
ziprasidone HCl | ZIPRASIDONE HCL | CAPSULE | Y | Age Restriction | |
ziprasidone HCl | GEODON | CAPSULE | Y | Age Restriction | |
aripiprazole | ARIPIPRAZOLE | SOLUTION | V | Age Restriction | |
aripiprazole | ARIPIPRAZOLE ODT | TAB RAPDIS | V | Age Restriction | |
aripiprazole | ABILIFY MYCITE | TABSENSSTR | V | Age Restriction | |
aripiprazole | ABILIFY MYCITE | TABSENSTPD | V | Age Restriction | |
asenapine | SECUADO | PATCH TD24 | V | Age Restriction | |
brexpiprazole | REXULTI | TAB DS PK | V | Age Restriction | |
brexpiprazole | REXULTI | TABLET | V | Age Restriction | |
clozapine | VERSACLOZ | ORAL SUSP | V | Age Restriction | |
clozapine | CLOZAPINE ODT | TAB RAPDIS | V | Age Restriction | |
iloperidone | FANAPT | TAB DS PK | V | Age Restriction | |
iloperidone | FANAPT | TABLET | V | Age Restriction | |
lumateperone tosylate | CAPLYTA | CAPSULE | V | Age Restriction | |
olanzapine | OLANZAPINE ODT | TAB RAPDIS | V | Age Restriction | |
olanzapine | ZYPREXA ZYDIS | TAB RAPDIS | V | Age Restriction | |
olanzapine/samidorphan malate | LYBALVI | TABLET | V | Age Restriction | |
paliperidone | INVEGA | TAB ER 24 | V | Age Restriction | |
paliperidone | PALIPERIDONE ER | TAB ER 24 | V | Age Restriction | |
pimavanserin tartrate | NUPLAZID | CAPSULE | V | PA Document | |
pimavanserin tartrate | NUPLAZID | TABLET | V | PA Document | Jan 26, 2017 |
quetiapine fumarate | QUETIAPINE FUMARATE | TABLET | V | Age and Quantity Limits | |
risperidone | RISPERIDONE ODT | TAB RAPDIS | V | Age Restriction |